PIIIW — P3 Health Partners Inc.

P3 Health Partners Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Membership: Approximately 116,000 members, in line with expectations.
• Capitated Revenue: $341.6 million for the quarter, approximately $982 per member per month (PMPM).
• Adjusted EBITDA: Loss of $45.9 million for the quarter; year-to-date adjusted EBITDA loss of $85.2 million. Normalized adjusted EBITDA loss year-to-date was approximately $70 million.
• Medical Margin: $4.4 million for the quarter ($13 PMPM), up from $500,000 ($1 PMPM) in the prior period. Year-to-date medical margin was $52.2 million ($50 PMPM).
• Operating Expenses: Reduced to $21.1 million, down 33% from $31.6 million in the prior year.

2. Strategic Updates and Business Highlights

• The company is focused on improving stability, operational discipline, and clinical foundation.
• Capitated revenue increased by 6%, with normalized medical cost trends remaining flat year-over-year.
• An operational improvement plan has resulted in over $100 million in EBITDA improvement year-over-year.
• A strategic joint venture is expected to add approximately 13,000 fully accretive ACO members, enhancing profitability and cash flow.
• The company is rationalizing its provider network to improve margins, exiting groups that do not align clinically or economically.

3. Forward Guidance and Outlook

• Revised full-year adjusted EBITDA guidance to a loss range of $110 million to $95 million, reflecting current expectations.
• The company anticipates $120 million to $170 million in EBITDA expansion opportunities for 2026, driven by improved alignment with population health, scaling clinical programs, and contractual improvements.
• The management is optimistic about achieving meaningful profitability in 2026.

4. Bad News, Challenges, or Points of Concern

• The adjusted EBITDA loss for the quarter and year-to-date reflects ongoing challenges in achieving profitability.
• The midyear settlement adjustments resulted in a $21 million unfavorable impact in Q3 due to discrepancies between estimated and actual settlements.
• There are ongoing headwinds related to one specific market and payor, contributing to the guidance reduction.
• Concerns about the visibility and timing of claims data from nondelegated plans, which could lead to further adjustments in the future.

5. Notable Q&A Insights

• Management discussed the motivation for payors to renegotiate contracts, emphasizing the need for collaboration on high-risk patients and quality metrics.
• There is a focus on ensuring payors have "skin in the game" through performance accountability.
• The guidance reduction was attributed to broader issues rather than being isolated to a single payor or market.
• Future expectations include a 5% improvement in premium rates across markets, with additional benefits anticipated from improved coding practices.
• Management expressed confidence in stabilizing the business and eliminating miscommunications with payors, aiming for consistent revenue and expense recognition moving forward.

Overall, while P3 Health Partners is navigating a transitional year with significant losses, the company is implementing strategic initiatives aimed at improving operational efficiency and positioning for profitability in 2026.